X-ZELL ranked among Top 50 health tech start-ups in Asia Singapore, October 2019 – X-ZELL has been ranked amongst the 50 leading health tech start-ups in Asia for the second year running. Every year, the prestigious list is compiled by Singapore-based analytics and...
New test capable of detecting clinically significant prostate cancer in small blood sample Bangkok/Basel, August 2019 (via PR Newswire) – An international research team at Mahidol University in Bangkok, Thailand, has demonstrated the potential for a new blood test to...
X-ZELL to launch AI-powered cell analysis project Singapore, July 2019 – Singapore-based rare cell detection specialist, X-ZELL, is about to embark on the most ambitious research and innovation project in the company’s history. Nicknamed Cloud Atlas, the landmark...
X-ZELL global HQ now open for business in Singapore Singapore, May 2019 – X-ZELL, only recently named one of Asia’s 20 most innovative health tech start-ups, today opened its new global headquarters at Paya Lebar Square in Singapore, conveniently located between...
X-ZELL shortlisted for 2019 HealthInvestor Asia Award Singapore, April 2019 – Rare cell detection specialist, X-ZELL, has been shortlisted as a Finalist for the 2019 HealthInvestor Asia Awards. According to HealthInvestor Asia, X-ZELL has been nominated in the...
X-ZELL Cryoimmunostaining™ Suite World Premiere Singapore, February 2019 – Rare cell detection specialist X-ZELL is proud to announce the world premiere of the world’s first 9-colour immunostaining system. Originally designed to enable the company’s headline-making...
